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disease due to HIV increased from 0.21% (95% CI 0.13–0.31%) to 0.53% (95%
CI 0.33–0.78%) and DALYs increased from 0.43 (95% CI 0.27–0.64) to 1.49 (95%
CI 0.93–2.17) million. There was marked regional variation with most DALYs lost
in sub-Saharan Africa (0.49 million, 95% CI 0.25–0.93) and the Asia-Pacific (0.23
million, 95% CI 0.14–0.34) regions. The highest population attributable fraction
was observed in sub-Saharan Africa, with HIV accounting for more than 10% of
the cardiovascular burden in Swaziland, Botswana, Lesotho and South Africa
Conclusions: We make a number of important and novel observations. First, the
crude rate for incident cardiovascular disease was 60 per 10,000 and is compa-
rable to other high-risk cardiovascular groups, such as diabetes mellitus. Second,
the risk of incident cardiovascular disease was nearly 2-fold higher in people living
with HIV. Third, the number of disability-adjusted life years due to HIV associated
cardiovascular disease has increased 3-fold over the last two decades. Finally,
there were major regional variations in both the attributable fraction and the rates
of cardiovascular disease due to HIV, with the majority of the burden seen in sub-
Saharan Africa followed by Asia and the Pacific. People living with HIV are twice
as likely to develop cardiovascular disease. The global burden of HIV associated
cardiovascular disease has tripled over the last two decades and is now respon-
sible for 1.5 million DALYs per annum with the greatest impact in sub-Saharan
Africa and the Asia-Pacific regions.
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Background: Currently, reducing the burden of chronic diseases such as dia-
betes, cardiovascular disease, cancer and mental disorders is a priority of EU
Member States and at EU Policy level, since they affect 8 out of 10 people aged
over 65 in Europe. European countries are in different stages of the communi-
cable to non-communicable disease transition, but in most countries CVD is still
the leading cause of death. It causes more than 2 million deaths every year in
the region, and is therefore are a big threat economically and socially. A large
variety of coordinated efforts between the European Union (EU), national gov-
ernments, non-profit organisations, private industry, and local communities exist.
Europe has made progress on lowering heart disease mortality, with 12 coun-
tries having reached the point where CVD is no longer the most common cause
of death. Beyond the quality of care provided in hospitals, large differences in
pre-hospital logistics, management, barriers to access services and time delays
strongly influence patients’ outcomes. There is a need for knowledge on effective
and efficient ways to prevent and improve the management of CVD, stroke and di-
abetes type-2. Our research shows how different countries approach the problem
and the large differences regarding CVD care provision within Europe.
Methods: Together with an external group of experts in cardiology, epidemiology
and European health systems in, the HCP designed a number of indicators on
Prevention, Procedures, Access to care and Outcomes to measure health care
provision in cardiac care (with a special interest in secondary prevention) in the
28 European member states plus Switzerland and Norway.
Data has been collected through government bodies addressing cardiac care,
physician cardiac organizations representatives and international data bases. The
data collected has been validated by national bodies of most countries included
in the project. Additional feedback on the information collected for some of the
indicators has been obtained through an online questionnaire to members of the
European Heart Network (EHN) and physicians in all participating countries.
Results/Conclusion: The data collected enables comparisons of the situation
in the 30 countries included in the study and highlights issues that need to be
prioritised. The results show national approaches, provision and performance on
cardiac care and in general point to 3 areas of improvement; Prevention (primary
and secondary), Deployment of medication (with a large variation in deployment
rates of essential drugs between countries) and Lack of or unexplained differ-
ences in CVD data.
Results: Serve as a tool for closing gaps between countries in cardiac care, and
to improve the European situation by tackling the problem at the source. The study
also allows the global community to learn from the positive examples in some of
the countries which have been able to improve the CVD situation.
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Background: Outcomes assessment is very important for improving health care
outcomes and control spending. Acute myocardial infarction (AMI) was chosen
for its prevalence, high morbidity and mortality, relevant mortality variability and
high treatment costs.
Purpose: To study the differences between hospitals in AMI mortality and the
associated waste from unjustified variation.
Methods: Patients with AMI discharged from public hospitals in our country in
2011–13 were selected and anonymized administrative data was utilized. The
relevant variables to explain the differences in mortality were: patient characteris-
tics (demographics, AMI type, comorbidities, and procedures), hospital character-
istics (hospital with “coronary green way”, volume, and university hospital), and
travel time to hospital. Generalized linear mixed models (1st level: patient, 2nd
level: hospital) were used and specifically binary logistic regression was applied.
The differences in mortality explained by each group of variables were evaluated
with a percentual rate of Pseudo-r2. We considered as waste the number of addi-
tional deaths in each hospital compared to patients with the same characteristics,
through the hospital random effect variance (difference of each hospital to the
global odds).
Results: 22.380 patients treated in 17 hospitals were included. Mortality rate
was 9.5%. The mortality rate varied between 5.4% (H11) and 14.1% (H3). Our
model explained 29.8% of the differences in mortality. Comorbidities explained
23.2% of mortality differences, demographic variables 7.8%, procedures 6.6%,
and type of AMI 2.8%. Angioplasty and primary angioplasty procedures were
protective factors, since all other procedures showed a comparatively increased
risk of death, particularly fibrinolysis without angioplasty (OR 5.9; CI 3.2–10.9).
Across all hospitals, there were 137 avoidable deaths, with a variation between
-81 deaths (hospital with lower mortality) and +133 deaths (hospital with higher
mortality). As shown in Fig. 1, there was a risk of death 3.5 times higher at H8
than at H7. The model showed excellent discrimination (area under the ROC
curve: 0.871).
Fig 1- Hospit effect vs Avoidable deaths
Conclusion: We observed significant differences in mortality in acute myocar-
dial infarction between hospitals, therefore indicating variability of practices. The
scale of avoidable deaths justifies an investigation of its causes, mainly in the
hospitals with worse performance. The hospital characteristics had little impact
on the detected differences, so the inefficiencies are probably more related with
the internal organization of hospitals and the way care is provided. These results
raise relevant concerns at the health system and hospitals levels, in particular
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